DJIA 17,745.98 -5.41 -0.03%
NASDAQ 5,128.79 17.05 0.33%
S&P 500 2,108.63 0.06 0.00%
market minute promo

199.29 0.53 (0.27%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALXN $199.29 0.27%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $200.41
Previous Close $198.76
Daily Range $189.40 - $203.06
52-Week Range $150.06 - $208.88
Market Cap $45.0B
P/E Ratio 68.07
Dividend (Yield) $0.00 (0.0%)
Volume 2,578,733
Average Daily Volume 2,066,980
Current FY EPS $5.29

Sector

Healthcare

Industry

Drug Makers

Alexion Pharmaceuticals, Inc. (ALXN) Description

A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Website: http://www.alexionpharm.com/

News & Commentary

How Rare-Disease Drugmaker Alexion Pharmaceuticals Found Its Groove in June

A trio of positive events sends rare disease-drug developer Alexion shooting higher by a double-digit percentage. Can the good times continue?

Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog

Alexion Pharmaceuticals (ALXN) Stock Gained on Earnings as Guidance Lowered

3 Stocks Pushing The Drugs Industry Downward

Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook - Tale of the Tape

Noteworthy ETF Outflows: RSP, CB, CELG, ALXN

Alexion Pharmaceuticals (ALXN) Q2 2015 Results - Earnings Call Webcast

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog

Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog

Analysts Divided On Biogen Following $85 Selloff

JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Is $1.7B Opportunity

See More ALXN News...

ALXN's Top Competitors

ALXN $199.29 (0.27%)
Current stock: ALXN
AMGN $171.69 (0.13%)
Current stock: AMGN
GILD $117.90 (1.89%)
Current stock: GILD
BIIB $317.00 (1.17%)
Current stock: BIIB